This site is intended for Healthcare professionals only.

Natco Pharma receives final approval for generic Azacitidine for injection for USA market

Natco Pharma receives final approval for generic Azacitidine for injection for USA market

Hyderabad: Natco Pharma Limited announced that it has got the final approval of Abbreviated New Drug Application (ANDA) from the U.S. Food and Drug Administration (FDA) for Azacitidine for Injection, 100mg per Vial, Single-Dose Vial, a generic version of Vidaza® by Celgene Corporation.

NATCO and its marketing partner Breckenridge Pharmaceutical, Inc. (BPI) plan to launch this product in the USA market in the near future.

Vidaza® is a prescription anti-cancer chemotherapy drug that is indicated to treat myelodysplastic syndrome (MDS).

Vidaza® generated total combined sales of $188 million for the twelve-month period ending April, 2017, based on industry sales data.

Source: PRESS RELEASE
0 comment(s) on Natco Pharma receives final approval for generic Azacitidine for injection for USA market

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted